PTX News Alert Pernix Therapeutics Holdings Inc. (PTX) 9.61 12/13/2014

New Post Public Reply Private Reply Replies (0) Message Board

Dec 13, 2014 at 1:32 AM

Pernix Therapeutics Holdings Inc. (PTX) 9.61 $PTX

Pernix Therapeutics Inc. to Present at the Oppenheimer Healthcare Conference in New York, NY
Business Wire - Mon Dec 01, 7:00AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX), a specialty pharmaceutical company, announced today that Doug Drysdale, Chairman, President and Chief Executive Officer and Sanjay Patel, Chief Financial Officer, are scheduled to present at the Oppenheimer Healthcare conference in NYC on December 11, 2014.
PTX: 9.61 (-0.38)

Pernix Therapeutics Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference
Business Wire - Mon Nov 24, 7:37AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX), a specialty pharmaceutical company, announced today that Douglas Drysdale, Chairman, President and Chief Executive Officer and Sanjay Patel, Chief Financial Officer, are scheduled to present at the Annual Piper Jaffray Healthcare Conference in New York, NY on December 2, 2014.
PTX: 9.61 (-0.38)

Pernix Submits sNDA for TREXIMET(R) Use in Adolescent Patients
Business Wire - Mon Nov 17, 6:39AM CST
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX) today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for TREXIMET (sumatriptan / naproxen sodium) to seek approval for use in adolescent patients, age 12 - 17, for the acute treatment of migraine with or without aura.
PTX: 9.61 (-0.38)

Nasdaq stocks posting largest percentage increases
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at 1 p.m.:
PGNX: 7.10 (+0.16), ICUI: 80.95 (-1.04), CDZI: 10.47 (+0.07), INSY: 41.00 (+1.82), PCMI: 9.17 (+0.07), PTX: 9.61 (-0.38), CYAN: 5.90 (-0.16), ACHN: 13.28 (-0.11), AGIO: 119.56 (+0.36), LIOX: 5.50 (-0.07), PLNR: 7.29 (+0.29)

Midday gainers / Losers
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 11:45AM CST

FSM: 4.36 (-0.05), HEAR: 3.82 (+0.22), JRJC: 7.62 (-0.31), CVO: 2.05 (-0.03), AAOI: 9.64 (-0.30), UNIS: 2.86 (-0.10), HIIQ: 6.48 (+0.03), CYAN: 5.90 (-0.16), PTX: 9.61 (-0.38), TRMR: 2.69 (unch), PRKR: 0.89 (unch), SUMR: 2.78 (+0.10), VSLR: 8.08 (+0.08), RVP: 4.59 (-0.01), ASCMA: 52.01 (-0.74), ICUI: 80.95 (-1.04), CALL: 7.70 (-0.05), DMD: 6.35 (+0.09), AST: 3.90 (-0.01), ASEI: 47.24 (-1.33)

Pernix Therapeutics Holdings' (PTX) CEO Douglas Drysdale on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:46PM CST

PTX: 9.61 (-0.38)

Pernix Therapeutics ups revenues 72% in Q3
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:15PM CST

PTX: 9.61 (-0.38)

Pernix Therapeutics Holdings (PTX) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Mon Nov 10, 8:55AM CST

PTX: 9.61 (-0.38)

Pernix Therapeutics misses by $0.02, beats on revenue
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:09AM CST

PTX: 9.61 (-0.38)

Pernix Therapeutics Reports Third Quarter 2014 Financial Results and Reaffirms Guidance
Business Wire - Mon Nov 10, 7:01AM CST
--Company Reiterates Full Year 2014 and 2015 Guidance
PTX: 9.61 (-0.38)

Technical Coverage of Pharma Stocks - Repros Therapeutics, Nektar Therapeutics, Akorn, AcelRx Pharma, and Pernix Therapeutics Holdings
PR Newswire - Mon Nov 03, 7:45AM CST
Investor-Edge has initiated coverage on the following equities: Repros Therapeutics Inc. (NASDAQ: RPRX), Nektar Therapeutics (NASDAQ: NKTR), Akorn Inc. (NASDAQ: AKRX), AcelRx Pharmaceuticals Inc. (NASDAQ: ACRX), and Pernix Therapeutics Holdings Inc. (NASDAQ: PTX). Free research on these five companies can be accessed at: http://investor-edge.com/register. On Friday, October 31, 2014, the NASDAQ Composite ended at 4,630.74, up 1.41%, the Dow Jones Industrial Average advanced 1.13%, to finish the day at 17,390.52, and the S&P 500 closed at 2,018.05, up 1.17%. The gains were broad based as all the sectors ended the session in positive. The S&P 500 Health Care Sector Index ended the day at 778.85, up 0.51%, with the index also advancing 10.60% in the previous three months. Register for your complimentary reports on these five stocks at:
ACRX: 6.40 (unch), PTX: 9.61 (-0.38), AKRX: 41.24 (+0.38), RPRX: 8.74 (+0.26), NKTR: 15.31 (-0.29)

Pernix reports November 10
Seeking Alpha - at Seeking Alpha - Mon Oct 27, 10:53AM CDT

PTX: 9.61 (-0.38)

Pernix Therapeutics to Report Q3 2014 Financial Results
Business Wire - Mon Oct 27, 7:45AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ

TX), a specialty pharmaceutical company, today announced that it will release its third quarter 2014 financial results on Monday, November 10, 2014 and has scheduled a conference call at 10:00 a.m. EST.
PTX: 9.61 (-0.38)

5 Stocks Under $10 Set to Soar
at The Street - Fri Oct 17, 8:41AM CDT
These under-$10 stocks look ready to trade higher from current levels.
GOMO: 5.01 (+0.01), ARWR: 5.76 (-0.17), PTX: 9.61 (-0.38), ADHD: 3.41 (+0.16), ZQK: 1.91 (+0.43), SALT: 2.05 (+0.03)

3 Stocks Under $10 Making Big Moves Higher
at The Street - Wed Oct 15, 6:00AM CDT
When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.
HGG: 7.39 (+0.37), PTX: 9.61 (-0.38), IVAC: 7.64 (+0.29)

5 Breakout Stocks Under $10 Set to Soar
at The Street - Fri Sep 26, 1:16PM CDT
These under-$10 stocks look ready to trade higher from current levels.
PTX: 9.61 (-0.38), TGS: 3.21 (-0.16), RPRX: 8.74 (+0.26), NQ: 5.35 (-0.09), CVGI: 6.51 (+0.03)

Pernix Therapeutics Closes Acquisition of Treximet. Raises $220m Senior Notes. Issues Updated 2014 Guidance.
Business Wire - Wed Aug 20, 7:01AM CDT
Pernix Therapeutics Holdings, Inc. (NASDAQ GM: PTX) ("Pernix" or the "Company"

, a specialty pharmaceutical company, announced today that it has closed its acquisition of Treximet(R) (sumatriptan / naproxen sodium) for the acute treatment of migraine attacks with or without aura in adults. Pernix first announced its agreement with GlaxoSmithKline (NYSE: GSK) to acquire the U.S rights to Treximet(R) on May 14. Pernix's expanded team of approximately 100 specialty sales professionals will support the sales and marketing of Treximet(R). The Company will hold a conference call on Wednesday, August 20 at 9:00 a.m. EDT to discuss this acquisition.
PTX: 9.61 (-0.38), GSK: 42.42 (-0.93), POZN: 9.12 (-0.08)

POZEN Announces U.S. Rights For TREXIMET(R) Have Been Acquired by Pernix Therapeutics
Business Wire - Wed Aug 20, 7:00AM CDT
POZEN Inc. (NASDAQ: POZN), a pharmaceutical company committed to transforming medicine that transforms lives, today announced that the acquisition of all of GlaxoSmithKline's (GSK) rights to Treximet(R) (sumatriptan / naproxen sodium) have been acquired by Pernix Therapeutics Holdings, Inc. (Pernix). The previously announced transaction was contingent upon Pernix securing financing, which is now complete. As part of the divestiture, GSK has assigned the Product Development and Commercialization Agreement between POZEN and GSK to Pernix, and POZEN and Pernix have amended the agreement to address rights of the parties and future development.
PTX: 9.61 (-0.38), GSK: 42.42 (-0.93), POZN: 9.12 (-0.08)

Pernix Therapeutics Reports Second Quarter 2014 Financial Results
Business Wire - Mon Aug 11, 7:30AM CDT
Pernix Therapeutics Holdings, Inc. ("Pernix" or the "Company"

(NASDAQ: PTX), a specialty pharmaceutical company, today announced financial results for the quarter and year-to-date periods ended June 30, 2014.
PTX: 9.61 (-0.38)

Market Updates on Pharma Stocks -- Theravance, Akorn, Endo Intl., Pernix Therapeutics, and Depomed
PR Newswire - Thu Aug 07, 8:20AM CDT
On Wednesday, August 6, 2014, the NASDAQ Composite ended at 4,355.05, up 0.05%, the Dow Jones Industrial Average advanced 0.08%, to finish the day at 16,443.34, and the S&P 500 closed the day flat at 1,920.24. The losses were broad based as six out of ten sectors ended the session in negative. The S&P 500 Health Care Sector Index ended the day at 700.41, down 0.12%, while the index has advanced 5.09% in the previous three months. Investor-Edge has initiated coverage on the following equities: Theravance Inc. (NASDAQ: THRX), Akorn Inc. (NASDAQ: AKRX), Endo International PLC (NASDAQ: ENDP), Pernix Therapeutics Holdings Inc. (NASDAQ: PTX), and Depomed Inc. (NASDAQ: DEPO). Free research on these five companies can be accessed at:
ENDP: 68.77 (-2.45), THRXV: 28.00 (+7.07), PTX: 9.61 (-0.38), AKRX: 41.24 (+0.38), DEPO: 15.15 (-0.27), THRX: 13.39 (-0.37)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Webull Faces Class Action: Investor Impact Deep Dive

What's Going On with Webull? Ah, Webull Corporation, you're in the hot seat now. If you blinked on October 7th, you might have missed a monumental 19.09% cliff dive in Webull's stock, tumbling down to a humble $5.89. The roar wasn't just the market reacting; it was the sonic boom of a class action lawsuit on their heels, alleging some slick legal sledding with misleading...

Junior Golf Stars Shine at Notah Begay III Championship

Ever wonder where the golf stars of tomorrow get their start? Well, you might find a few of 'em teeing off at the Notah Begay III Junior Golf National Championship. This year, the spotlight is shining on the fairways of the Coushatta Resort in Louisiana. And let me tell you, the talent pool is something to behold. Young golfers from across the globe are swinging their way...

Marc Ryan Joins ABCS Insights as Chief Product Officer

Shaping the Future of Advertising Effectiveness In the ever-evolving ad measurement arena, where understanding what works can make or break a company, ABCS Insights has tossed a game-changing hat into the ring. They've just announced Marc Ryan as their new Chief Product Officer. Now, I’ve seen seasoned execs shuffle seats countless times, but this one’s...

ATTACK SHARK's X60: A New Era in Gaming Audio

Gaming Audio Gets a Power Boost with X60 We're diving headfirst into an era where gaming headsets promise more bells and whistles than ever before. This isn't just some random gadget plopped on the market. ATTACK SHARK's X60 Gaming Headset is strutting in, guns blazing, ready to take on the heavyweights in the competitive gaming world. It's not just about being another...

Cyclists and Trains: A New Chapter in Urban Travel

Rolling Without Engines: LA to SD Picture this: over 75 cyclists and their compact, foldable steeds embarking on a train journey from Los Angeles to the sun-drenched streets of San Diego. In an era where travel is often synonymous with congestion and pollution, this collaboration between Amtrak's Pacific Surfliner and Brompton Bicycle was like a breath of fresh sea air....

Tiny Fish Revolutionizes Vertebrate Gene Studies

From Small Fish to Big Discoveries: Meet Danionella cerebrum Who would've thought a diminutive fish with a see-through body would give a jolt to the study of vertebrate genomes? Thanks to Danionella cerebrum, researchers at the Whitehead Institute have created the very first complete whole-body single-cell atlas of an adult vertebrate. Forget the Wall Street clamor for a...

Service Pros Adds Windshield Repair to Lineup

Revving Up the Service Engine Alright, folks, buckle up because Service Pros Auto Glass, our local go-to for windshield replacements, is cranking up their game. They're stepping into the windshield repair arena across Florida and South Carolina, aiming to save you a buck and keep you safe behind the wheel. That's a double win if you ask me. A Closer Look at the Details...

Navigating Homeowner Deductibles: Balancing Costs

Understanding the Basics: Premiums and Deductibles Picture sorting through bills with a cup of lukewarm coffee, wondering if there’s a smarter way to handle homeowner insurance. Chuck Montgomery cuts through the fluff, talking turkey about balancing insurance dollars. One part of the game is deciding your deductible, the sum you fork over before insurance steps in...

Palmetto Publishing's M&A Guide Aims to Boost Home Services

Palmetto's New Release: Mergers & Acquisitions Focus Man, Palmetto Publishing just dropped a bombshell for home services aficionados with their latest M&A guide. Now, if you’re like me, swimming in stocks and always looking for that next big exit play, this one’s tailor-made for you. Mergers and acquisitions might not sound as flashy as the tech darlings or...

Jack Henry's Q1 2027 Deconversion Revenue Hits $17.9M

Jack Henry Surprises with Strong Deconversion Revenue You're probably thinking, deconversion revenue—what on earth is that? Imagine you're in the financial tech business and one of your bigwig clients decides to merge or get gobbled up by another institution. They move shop, and voila, you've got some unexpected money flowing in due to that exit. That's deconversion...